New class of anti-influenza macromolecules based on beta-cyclodextrin
A new class of anti-influenza macromolecules were synthesized based on a cyclodextrin to target conserved viral domains irreversibly. 6’ sialyl-N-acetyllactosamine
A forum for researchers, students and applicants in the field of cyclodextrin technology
A new class of anti-influenza macromolecules were synthesized based on a cyclodextrin to target conserved viral domains irreversibly. 6’ sialyl-N-acetyllactosamine
Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential
The most interesting finding of Crui et al. in their recently published paper [1] for the readers of the Cyclodextrin
The 30th International Carbohydrate Symposium (ICS2020) planned in July 12-17, 2020, at Shanghai has been cancelled. The ICS2020 was aimed
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that
Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis. Novartis Chief Executive Vas Narasimhan said his Sandoz
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral
A recent review in Science [1] reported that WHO on 20 March announced the launch of SOLIDARITY, an unprecedented, coordinated
Pharmaceutics, a peer-reviewed open access journal (Impact Factor: 4.77) on the science and technology of pharmaceutics and biopharmaceutics, published monthly
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple